Seladelpar: New hope for patients with primary biliary cholangitis

The study by Hirschfield et al. 1 Hirschfield G.M. Bowlus C.L. Mayo M.J. Kremer A.E. Vierling J.M. Kowdley K.V. Levy C. Villamil A. Ladrón de Guevara Cetina A.L. Janczewska E. et al. A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis. N. Engl. J. Med. 2024; 390: 783-794 Crossref PubMed Scopus (0) Google Scholar demonstrated safety profile and clinically significant effectiveness of the peroxisome proliferator-activated receptor delta (PPARδ) agonist seladelpar in patients with primary biliary cholangitis, highlighting its plausible use as a second-line treatment to reduce disease activity and pruritus. The study by Hirschfield et al. 1 Hirschfield G.M. Bowlus C.L. Mayo M.J. Kremer A.E. Vierling J.M. Kowdley K.V. Levy C. Villamil A. Ladrón de Guevara Cetina A.L. Janczewska E. et al. A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis. N. Engl. J. Med. 2024; 390: 783-794 Crossref PubMed Scopus (0) Google Scholar demonstrated safety profile and clinically significant effectiveness of the peroxisome proliferator-activated receptor delta (PPARδ) agonist seladelpar in patients with primary biliary cholangitis, highlighting its plausible use as a second-line treatment to reduce disease activity and pruritus.